QIAGEN
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The last earnings update was 45 days ago. More info.
Add to Portfolio Compare Print
QGEN Share Price and Events
7 Day Returns
1 Year Returns
QGEN Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| QIAGEN (QGEN) | 3% | 5.9% | 3.3% | 11% | 86.6% | 60.1% |
| US Life Sciences | 4.5% | 10.3% | 8.2% | 30.4% | 103.4% | 120% |
| US Market | 2.2% | 3.4% | 4.4% | 3.8% | 43% | 40.9% |
1 Year Return vs Industry and Market
- QGEN underperformed the Life Sciences industry which returned 30.4% over the past year.
- QGEN outperformed the Market in United States of America which returned 3.8% over the past year.
Value
Is QIAGEN undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
QIAGEN
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for QIAGEN.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 17 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 9.2% |
| Perpetual Growth Rate | 10-Year US Government Bond Rate | 2.7% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year US Govt Bond Rate | 2.7% |
| Equity Risk Premium | S&P Global | 6% |
| Life Sciences Unlevered Beta | Simply Wall St/ S&P Global | 0.99 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.99 (1 + (1- 25%) (19.74%)) |
1.092 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
1.09 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.092 * 5.96%) |
9.24% |
Discounted Cash Flow Calculation for NYSE:QGEN using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for QIAGEN is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (USD, Millions) | Source |
Present Value Discounted (@ 9.24%) |
|
|---|---|---|---|
| 2019 | 299.98 | Analyst x9 | 274.61 |
| 2020 | 356.19 | Analyst x9 | 298.50 |
| 2021 | 399.90 | Analyst x6 | 306.79 |
| 2022 | 429.10 | Analyst x2 | 301.35 |
| 2023 | 453.79 | Est @ 5.75% | 291.74 |
| 2024 | 475.78 | Est @ 4.85% | 280.02 |
| 2025 | 495.82 | Est @ 4.21% | 267.14 |
| 2026 | 514.50 | Est @ 3.77% | 253.76 |
| 2027 | 532.28 | Est @ 3.46% | 240.33 |
| 2028 | 549.51 | Est @ 3.24% | 227.13 |
| Present value of next 10 years cash flows | $2,741.37 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= $549.51 × (1 + 2.73%) ÷ (9.24% – 2.73%) |
$8,675.35 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= $8,675.35 ÷ (1 + 9.24%)10 |
$3,585.79 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= $2,741.37 + $3,585.79 |
$6,327.16 |
| Equity Value per Share (USD) |
= Total value / Shares Outstanding
= $6,327.16 / 226.21 |
$27.97 |
| Calculation | Result | |
|---|---|---|
| Value per share (USD) | From above. | $27.97 |
| Current discount | Discount to share price of
$40.71
= -1 x ($40.71 - $27.97) / $27.97 |
-45.5% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
- The current share price of QIAGEN is above its future cash flow value.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for QIAGEN's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
QIAGEN's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2019-03-31) in USD | $0.83 |
| NYSE:QGEN Share Price ** | NYSE (2019-06-21) in USD | $40.71 |
| United States of America Life Sciences Industry PE Ratio | Median Figure of 21 Publicly-Listed Life Sciences Companies | 39.17x |
| United States of America Market PE Ratio | Median Figure of 3,093 Publicly-Listed Companies | 17.88x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of QIAGEN.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NYSE:QGEN Share Price ÷ EPS (both in USD) = 40.71 ÷ 0.83 |
49.14x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- QIAGEN is overvalued based on earnings compared to the US Life Sciences industry average.
- QIAGEN is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does
QIAGEN's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | 49.14x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 17 Analysts |
20.2%per year |
| United States of America Life Sciences Industry PEG Ratio | Median Figure of 19 Publicly-Listed Life Sciences Companies | 2.62x |
| United States of America Market PEG Ratio | Median Figure of 2,133 Publicly-Listed Companies | 1.54x |
*Line of best fit is calculated by linear regression .
| Calculation | Outcome | |
|---|---|---|
| PEG Ratio | = PE Ratio ÷ Net Income Annual Growth Rate = 49.14x ÷ 20.2% |
2.43x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- QIAGEN is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on
QIAGEN's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2019-03-31) in USD | $11.48 |
| NYSE:QGEN Share Price * | NYSE (2019-06-21) in USD | $40.71 |
| United States of America Life Sciences Industry PB Ratio | Median Figure of 38 Publicly-Listed Life Sciences Companies | 4.78x |
| United States of America Market PB Ratio | Median Figure of 5,254 Publicly-Listed Companies | 1.81x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NYSE:QGEN Share Price ÷ Book Value per Share (both in USD) = 40.71 ÷ 11.48 |
3.55x |
* Primary Listing of QIAGEN.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- QIAGEN is good value based on assets compared to the US Life Sciences industry average.
Value checks
We assess QIAGEN's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check) QIAGEN has a total score of 1/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
Future Performance
How is QIAGEN expected to perform in the next 1 to 3 years based on estimates from 17 analysts?
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- QIAGEN's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
- QIAGEN's earnings growth is expected to exceed the United States of America market average.
- QIAGEN's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NYSE:QGEN Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 17 Analysts | 20.2% |
| NYSE:QGEN Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 17 Analysts | 7.7% |
| United States of America Life Sciences Industry Earnings Growth Rate | Market Cap Weighted Average | 16.1% |
| United States of America Life Sciences Industry Revenue Growth Rate | Market Cap Weighted Average | 7.2% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 14% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7.4% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (2 months ago) | See Below |
| Future Estimates | Average of up to 17 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 2,154 | 740 | 498 | 4 |
| 2022-12-31 | 1,983 | 627 | 400 | 7 |
| 2021-12-31 | 1,850 | 554 | 339 | 13 |
| 2020-12-31 | 1,714 | 488 | 271 | 17 |
| 2019-12-31 | 1,580 | 442 | 213 | 16 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2019-03-31 | 1,507 | 356 | 188 |
| 2018-12-31 | 1,502 | 359 | 190 |
| 2018-09-30 | 1,496 | 325 | 90 |
| 2018-06-30 | 1,482 | 324 | 78 |
| 2018-03-31 | 1,453 | 275 | 55 |
| 2017-12-31 | 1,418 | 287 | 40 |
| 2017-09-30 | 1,387 | 311 | 89 |
| 2017-06-30 | 1,362 | 323 | 75 |
| 2017-03-31 | 1,347 | 353 | 82 |
| 2016-12-31 | 1,338 | 342 | 80 |
| 2016-09-30 | 1,320 | 328 | 123 |
| 2016-06-30 | 1,296 | 331 | 123 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (2 months ago) | See Below |
| Future Estimates | Average of up to 17 Analyst Estimates (S&P Global) | See Below |
All data from QIAGEN Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 1.89 | 1.89 | 1.89 | 1.00 |
| 2022-12-31 | 1.60 | 1.69 | 1.50 | 2.00 |
| 2021-12-31 | 1.34 | 1.49 | 1.20 | 3.00 |
| 2020-12-31 | 1.14 | 1.29 | 1.02 | 5.00 |
| 2019-12-31 | 0.86 | 0.89 | 0.79 | 4.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2019-03-31 | 0.83 |
| 2018-12-31 | 0.84 |
| 2018-09-30 | 0.40 |
| 2018-06-30 | 0.34 |
| 2018-03-31 | 0.24 |
| 2017-12-31 | 0.18 |
| 2017-09-30 | 0.39 |
| 2017-06-30 | 0.33 |
| 2017-03-31 | 0.36 |
| 2016-12-31 | 0.36 |
| 2016-09-30 | 0.55 |
| 2016-06-30 | 0.54 |
*GAAP earnings excluding extraordinary items.
Future performance checks
We assess QIAGEN's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
QIAGEN has a total score of 4/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
Past Performance
How has QIAGEN performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- QIAGEN's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.
- QIAGEN's 1-year earnings growth exceeds its 5-year average (240.9% vs -1.6%)
- QIAGEN's earnings growth has exceeded the US Life Sciences industry average in the past year (240.9% vs 45.3%).
Earnings and Revenue History
All data from QIAGEN Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2019-03-31 | 1,506.93 | 187.61 | 517.27 | 163.12 |
| 2018-12-31 | 1,501.85 | 190.38 | 506.42 | 161.85 |
| 2018-09-30 | 1,495.54 | 89.74 | 472.69 | 162.13 |
| 2018-06-30 | 1,481.60 | 77.90 | 458.57 | 158.40 |
| 2018-03-31 | 1,453.40 | 55.04 | 465.85 | 156.67 |
| 2017-12-31 | 1,417.54 | 40.39 | 477.64 | 154.08 |
| 2017-09-30 | 1,387.19 | 88.71 | 466.52 | 145.36 |
| 2017-06-30 | 1,361.90 | 75.03 | 479.58 | 143.10 |
| 2017-03-31 | 1,347.32 | 82.34 | 480.19 | 147.20 |
| 2016-12-31 | 1,337.99 | 80.40 | 469.60 | 149.84 |
| 2016-09-30 | 1,320.02 | 123.40 | 484.98 | 156.98 |
| 2016-06-30 | 1,295.89 | 122.53 | 471.41 | 156.51 |
| 2016-03-31 | 1,280.94 | 126.37 | 450.00 | 148.08 |
| 2015-12-31 | 1,280.99 | 130.15 | 444.66 | 146.83 |
| 2015-09-30 | 1,292.86 | 104.37 | 474.91 | 151.39 |
| 2015-06-30 | 1,314.75 | 105.13 | 483.73 | 157.29 |
| 2015-03-31 | 1,326.13 | 112.86 | 487.34 | 161.62 |
| 2014-12-31 | 1,344.78 | 116.37 | 490.08 | 163.67 |
| 2014-09-30 | 1,345.45 | 150.94 | 487.40 | 163.50 |
| 2014-06-30 | 1,331.11 | 156.95 | 487.42 | 156.38 |
| 2014-03-31 | 1,315.48 | 72.36 | 486.52 | 152.11 |
| 2013-12-31 | 1,301.98 | 69.07 | 486.10 | 146.07 |
| 2013-09-30 | 1,287.43 | 44.03 | 497.86 | 111.81 |
| 2013-06-30 | 1,269.61 | 32.49 | 512.22 | 108.48 |
| 2013-03-31 | 1,261.61 | 117.58 | 503.13 | 105.46 |
| 2012-12-31 | 1,254.46 | 129.51 | 450.12 | 122.48 |
| 2012-09-30 | 1,242.35 | 90.71 | 444.54 | 123.08 |
| 2012-06-30 | 1,226.94 | 96.69 | 421.88 | 124.72 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- QIAGEN has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- QIAGEN used its assets less efficiently than the US Life Sciences industry average last year based on Return on Assets.
- QIAGEN has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
Past performance checks
We assess QIAGEN's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
QIAGEN has a total score of 3/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
Health
How is QIAGEN's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up QIAGEN's finances.
The net worth of a company is the difference between its assets and liabilities.
- QIAGEN is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- QIAGEN's long term commitments exceed its cash and other short term assets.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is not covered by short term assets, assets are 0.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from QIAGEN Company Filings, last reported 2 months ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2019-03-31 | 2,606.06 | 1,817.67 | 780.39 |
| 2018-12-31 | 2,634.97 | 2,193.04 | 1,393.69 |
| 2018-09-30 | 2,527.30 | 1,793.32 | 920.73 |
| 2018-06-30 | 2,523.86 | 1,792.19 | 900.19 |
| 2018-03-31 | 2,580.54 | 1,814.78 | 1,014.19 |
| 2017-12-31 | 2,541.00 | 1,788.72 | 1,016.91 |
| 2017-09-30 | 2,566.60 | 1,769.99 | 974.95 |
| 2017-06-30 | 2,505.37 | 1,396.33 | 608.85 |
| 2017-03-31 | 2,429.80 | 1,073.76 | 273.39 |
| 2016-12-31 | 2,607.10 | 1,068.10 | 532.18 |
| 2016-09-30 | 2,665.70 | 1,075.84 | 464.34 |
| 2016-06-30 | 2,626.51 | 1,072.41 | 406.44 |
| 2016-03-31 | 2,624.60 | 1,070.89 | 447.26 |
| 2015-12-31 | 2,568.07 | 1,049.95 | 420.83 |
| 2015-09-30 | 2,520.28 | 1,058.91 | 429.53 |
| 2015-06-30 | 2,537.44 | 1,053.59 | 367.55 |
| 2015-03-31 | 2,478.74 | 1,053.07 | 392.29 |
| 2014-12-31 | 2,658.00 | 1,173.20 | 576.70 |
| 2014-09-30 | 2,713.67 | 1,176.78 | 692.02 |
| 2014-06-30 | 2,754.78 | 1,189.36 | 654.77 |
| 2014-03-31 | 2,732.59 | 1,186.70 | 677.97 |
| 2013-12-31 | 2,723.87 | 850.20 | 380.23 |
| 2013-09-30 | 2,676.24 | 863.96 | 355.75 |
| 2013-06-30 | 2,595.30 | 864.16 | 373.20 |
| 2013-03-31 | 2,690.79 | 865.41 | 460.54 |
| 2012-12-31 | 2,794.09 | 862.52 | 485.15 |
| 2012-09-30 | 2,711.79 | 687.32 | 311.31 |
| 2012-06-30 | 2,641.66 | 682.42 | 266.33 |
- QIAGEN's level of debt (67.6%) compared to net worth is high (greater than 40%).
- The level of debt compared to net worth has increased over the past 5 years (43.4% vs 67.6% today).
- Debt is well covered by operating cash flow (20.2%, greater than 20% of total debt).
- Interest payments on debt are well covered by earnings (EBIT is 5.9x coverage).
Financial health checks
We assess QIAGEN's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) QIAGEN has a total score of 3/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
Dividends
What is QIAGEN's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
QIAGEN
shares you are expected to receive
$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate QIAGEN's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate QIAGEN's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 17 Analyst Estimates (S&P Global) | See Below |
| United States of America Life Sciences Industry Average Dividend Yield | Market Cap Weighted Average of 7 Stocks | 0.4% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 2012 Stocks | 2.4% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.4% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.7% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-12-31 | ||
| 2022-12-31 | ||
| 2021-12-31 | 0.00 | 2.00 |
| 2020-12-31 | 0.00 | 3.00 |
| 2019-12-31 | 0.00 | 3.00 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as QIAGEN has not reported any payouts.
- Unable to verify if QIAGEN's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess QIAGEN's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can QIAGEN afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) QIAGEN has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
Management
CEO
| COMPENSATION | $2,025,315 |
| AGE | 52 |
| TENURE AS CEO | 15.4 years |
CEO Bio
Mr. Peer Michael Schatz serves as Managing Director of QIAGEN Hannover GmbH. Mr. Schatz has been the Chief Executive Officer and Managing Director of Qiagen NV since January 1, 2004. He has been Member of Management Board of Qiagen NV since 1998 and served as its Chairman of Management Board. Mr. Schatz served as the Chief Financial Officer of Qiagen NV from 1993 to 2003 and also served as its Treasurer and Secretary. He was a Partner in a private management buyout group in Switzerland and worked in finance and systems positions in Sandoz, Ltd. and Computerland AG as well as in finance, operations, management and sales positions in various start up companies in the computer and software trading industry in Europe and U.S. Mr. Schatz serves as the Chairman of the Supervisory Board of Qiagen S.A and Courtaboeuf Cedex. He has been the Chairman of Supervisory Board at Exiqon A/S since February 7, 2017. He serves as the Chairman of Qiagen Marseille Société Anonyme (formerly Ipsogen SA). He serves as the Vice Chairman of the Board of Mulligan BioCapital GmbH (formerly Mulligan BioCapital AG). He served as Vice Chairman of the Supervisory Board of Evotec AG (formerly Evotec OAI AG) from June 1998 to August 2008. He serves as a Director of QIAGEN North American Holdings Inc. He has been a Member of the Supervisory Board of Hamburg/D Qiagen AS since August 2002, Qiagen Genomics Inc. since August 2002, Qiagen Inc. since January 2002, Qiagen K.K., Qiagen Ltd., Crawly West, Qiagen North American Holding, Inc. since August 2002, Qiagen Operon, Inc., Alameda since August 2002, Qiagen Pty Ltd., Clifton Hill, Qiagen S.p.A., Milan/I Qiagen Sciences, Inc. since August 2002, Sawady Technology Co, Ltd., Xeragon, Inc. since April 2002. He has been a Director at Qiagen Marseille Société Anonyme since July 12, 2011. He has been a Member of Supervisory Board of Exiqon A/S since July 5, 2016. Mr. Schatz served as a member of the German Corporate Governance Commission from 2002 to 2012. He is Managing Director of PS Capital Management GmbH. He is Member of Advisory Board at HSBC Trinkaus & Burkhardt AG since March 2018. He is a board member of AdvaMedDx, an advocacy dedicated to issues facing the in vitro diagnostics industry in the United States and Europe, and ALDA (the Analytical, Life Science and Diagnostics Association), a trade association of developers and suppliers in these fields. He serves as a member of the Advisory Board of the Frankfurt Stock Exchange. Mr. Schatz is a Member of the Beirat in ACS Moschner & Co. GmbH and Venture Capital Partners KEG and a Member of the Boersenrat of Frankfurter Wertpapierboerse. He was Member of the Supervisory Board at Evotec AG until August 28, 2008. He obtained his M.B.A. degree in Finance from the University of Chicago Graduate School of Business in 1991 and graduated from the University of St. Gallen, Switzerland, with a Master's degree in Finance in 1989.
CEO Compensation
- Peer's compensation has been consistent with company performance over the past year, both up more than 20%.
- Peer's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the QIAGEN management team in years:
- The tenure for the QIAGEN management team is about average.
Management Team
Peer Schatz
CEO, MD & Member of Management Board
$2M
52
15.4 yrs
Roland Sackers
CFO, MD & Member of Management Board
$889K
49
15.4 yrs
Barthold Piening
Senior VP & Head of Global Operations
60
0.5 yrs
John Gilardi
Vice President of Corporate Communications & Investor Relations
8.7 yrs
Jean-Pascal Viola
Head of Corporate Business Development
4.1 yrs
Annette Koch
Senior VP & Chief Human Resources Officer
1.4 yrs
Thomas Schweins
Senior Vice President of Life Science Business Area
1.4 yrs
Manuel Méndez
Senior Vice President of Global Commercial Operations
50
4.7 yrs
Thierry Bernard
Senior Vice President of Molecular Diagnostics Business Area
4.3 yrs
Jonathan Sheldon
Senior Vice President of Bioinformatics Business Area
1.4 yrs
Board of Directors Tenure
Average tenure and age of the QIAGEN board of directors in years:
- The tenure for the QIAGEN board of directors is about average.
Board of Directors
Sven Björklund
Supervisory Board Chairman
$124K
62
1 yrs
Metin Colpan
Supervisory Director
$76K
63
15.4 yrs
Liz Tallett
Supervisory Director
$97K
69
8 yrs
Larry Rosen
Supervisory Director
$83K
60
6 yrs
Stéphane Bancel
Supervisory Director
$90K
45
6 yrs
Elaine Mardis
Supervisory Director
$64K
55
5 yrs
Ross Levine
Supervisory Director
$64K
46
3.4 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 07. Mar 19 | Sell | Lawrence Rosen | Individual | 07. Mar 19 | 07. Mar 19 | -4,886 | $38.86 | $-189,870 | ||
Management checks
We assess QIAGEN's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) QIAGEN has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
News
Simply Wall St News
What Are Analysts Saying About The Future Of QIAGEN N.V.'s (NYSE:QGEN)?
(NYSE:QGEN) released its earnings in March 2019, it seems that analyst forecasts are fairly optimistic, with earnings expected to grow by 23% in the upcoming year against the past 5-year average growth rate of -1.6%. … To understand the overall trajectory of QGEN's earnings growth over these next fews years, I've fitted a line through these analyst earnings forecast to determine an annual growth rate from the slope. … NYSE:QGEN Past and Future Earnings, June 18th 2019 By 2022, QGEN's earnings should reach US$361m, from current levels of US$190m, resulting in an annual growth rate of 20%.
Simply Wall St - – Full articleHere's Why I Think QIAGEN (NYSE:QGEN) Is An Interesting Stock
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it completely lacks a track record of revenue and profit. … In contrast to all that, I prefer to spend time on companies like QIAGEN (NYSE:QGEN), which has not only revenues, but also profits. … See our latest analysis for QIAGEN How Fast Is QIAGEN Growing?
Simply Wall St - – Full articleDoes QIAGEN N.V.'s (NYSE:QGEN) Stock Price Account For Its Growth?
(NYSE:QGEN) is considered a high-growth stock, but its last closing price of $38.2 left some investors wondering if this high future earnings potential can be rationalized by its current price tag. … This tells us that QIAGEN is overvalued compared to the US market average ratio of 17.41x , and overvalued based on current earnings compared to the Life Sciences industry average of 34.39x. … This tells us that when we include its growth in our analysis QIAGEN's stock can be considered overvalued , based on the fundamentals.
Simply Wall St - – Full articleHow Much is QIAGEN N.V.'s (NYSE:QGEN) CEO Getting Paid?
This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … Check out our latest analysis for QIAGEN How Does Peer Schatz's Compensation Compare With Similar Sized Companies? … Peer Schatz is paid less than what is normal at similar size companies, and the total shareholder return has been pleasing over the last three years.
Simply Wall St - – Full articleNeed To Know: QIAGEN N.V. (NYSE:QGEN) Insiders Have Been Selling Shares
So we'll take a look at whether insiders have been buying or selling shares in QIAGEN N.V. … But logic dictates you should pay some attention to whether insiders are buying or selling shares. … That means that an insider was selling shares at around the current price of US$38.50
Simply Wall St - – Full articleWhy QIAGEN N.V.'s (NYSE:QGEN) High P/E Ratio Isn't Necessarily A Bad Thing
The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). … Looking at earnings over the last twelve months, QIAGEN has a P/E ratio of 45.59. … Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS)
Simply Wall St - – Full articleIf You Had Bought QIAGEN (NYSE:QGEN) Stock Five Years Ago, You Could Pocket A 94% Gain Today
(NYSE:QGEN) shareholders have enjoyed a 94% share price rise over the last half decade, well in excess of the market return of around 47% (not including dividends). … During five years of share price growth, QIAGEN achieved compound earnings per share (EPS) growth of 22% per year. … The EPS growth is more impressive than the yearly share price gain of 14% over the same period.
Simply Wall St - – Full articleA Closer Look At QIAGEN N.V.'s (NYSE:QGEN) Uninspiring ROE
QIAGEN has a ROE of 7.2%, based on the last twelve months. … Another way to think of that is that for every $1 worth of equity in the company, it was able to earn $0.072. … Return on Equity = Net Profit ÷ Shareholders' Equity
Simply Wall St - – Full articleAt US$39.93, Is It Time To Put QIAGEN N.V. (NYSE:QGEN) On Your Watch List?
saw a significant share price rise of over 20% in the past couple of months on the NYSE. … With many analysts covering the mid-cap stock, we may expect any price-sensitive announcements have already been factored into the stock’s share price? … However, what if the stock is still a bargain.
Simply Wall St - – Full articleWill QIAGEN N.V.'s (NYSE:QGEN) Earnings Grow In The Next 12 Months?
Looking at QIAGEN N.V.'s (NYSE:QGEN) earnings update on 31 December 2018, … the consensus outlook from analysts appear fairly confident, … the past 5-year average growth rate of -4.0%.
Simply Wall St - – Full articleCompany Info
Description
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions. It also provides Ingenuity Variant Analysis, an application for analysis and interpretation of human sequencing data generated with next-generation sequencing (NGS) technologies; QIAGEN Clinical Insight, an evidence-based variant classification; CLC Genomics Workbench for the analysis and visualization of data from various NGS platforms; and GeneGlobe, a Web-based portal that enables researchers to search and order bioinformatics solutions and linking biological interpretation from pre-designed and custom PCR assay kits, NGS assay panels, and other products. In addition, the company offers instrumentation systems for laboratories. Its automation platforms include QIAsymphony, a modular system; QIAsymphony SP for sample preparation; QIAsymphony AS for assay setup; Rotor-Gene Q, a rotary real-time PCR cycler system; QIAstat-Dx for molecular analysis of common syndromes; GeneReader NGS System, a sample to insight NGS solution for laboratories to deliver actionable results; NeuMoDx 288 and NeuMoDx 96 for automation of higher-throughput PCR testing in clinical laboratories; and QIAcube and QIAcube connect workstations, which provides versatile solutions for automated sample processing; It serves molecular diagnostics, applied testing, pharma, and academia customers. QIAGEN N.V. has collaboration agreements with Ares Genetics and Laboratory Corporation of America Holdings; Inovio Pharmaceuticals Inc.; and DiaSorin. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
Details
| Name: | QIAGEN N.V. |
| QGEN | |
| Exchange: | NYSE |
| Founded: | 1986 |
| $9,208,891,285 | |
| 226,207,106 | |
| Website: | http://www.qiagen.com |
| Address: |
QIAGEN N.V. Hulsterweg 82, Venlo, Limburg, 5912 PL, Netherlands |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NYSE | QGEN | Common Shares | New York Stock Exchange | US | USD | 28. Jun 1996 | |
| DB | QIA | Common Shares | Deutsche Boerse AG | DE | EUR | 28. Jun 1996 | |
| XTRA | QIA | Common Shares | XETRA Trading Platform | DE | EUR | 28. Jun 1996 | |
| LSE | 0RLT | Common Shares | London Stock Exchange | GB | EUR | 28. Jun 1996 | |
| SWX | QGEN | Common Shares | SIX Swiss Exchange | CH | CHF | 28. Jun 1996 | |
| WBAG | QGEN | Common Shares | Wiener Boerse AG | AT | EUR | 28. Jun 1996 | |
| BATS-CHIXE | QIAD | Common Shares | BATS 'Chi-X Europe' | GB | EUR | 28. Jun 1996 |
Number of employees
Current staff
Industry
| Life Sciences Tools and Services | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/06/22 23:44 |
| End of day share price update: | 2019/06/21 00:00 |
| Last estimates confirmation: | 2019/06/21 |
| Last earnings filing: | 2019/05/08 |
| Last earnings reported: | 2019/03/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
